MedTrace Logo

Prevention of COVID-19 Infection to Severe Pneumonia or ARDS

NCT04569227 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2021-06-10

No results posted yet for this study

Summary

A trial of EC-18 in patients with mild/moderate pneumonia due to COVID-19

Conditions

  • Covid19 Pneumonia

Interventions

DRUG

EC-18

2000 mg PO daily

DRUG

Placebo

PO daily

Sponsors & Collaborators

  • Enzychem Lifesciences Corporation

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-04-30
Primary Completion
2021-09-30
Completion
2021-11-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04569227 on ClinicalTrials.gov